| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615752 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 8 Pages |
Abstract
Overall effectiveness and tolerability outcomes were similar between modified hyperCVAD and bortezomib-hyperCAD, with both regimens showing an impressive response rate among refractory and heavily pretreated patients with relapsed MM.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Megan M. Saraceni, Emma Scott, Richard T. Maziarz, Matthew B. Siegel, Solange Bassale, Susie Jiing, Eva Medvedova,